AB Science
Paris, France· Est. 2001
AB Science is currently developing two main compounds, masitinib, a highly selective tyrosine kinase inhibitor and AB8939.
Private Company
Total funding raised: $95M
About
AB Science is currently developing two main compounds, masitinib, a highly selective tyrosine kinase inhibitor and AB8939.
Small Molecules
Funding History
4Total raised:$95M
PIPE$25MJun 15, 2018
IPO$40MJun 30, 2010
Series B$20MJun 15, 2005
Series A$10MJun 15, 2001